Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune ...
DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...
bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference, and it was chosen from over 10,500+ submissions. bit.bio will host an expert panel ...
Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...
Explore how regenerative medicine is transforming healing and restoration in healthcare, and discover its potential benefits ...
Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
Developing cardiac inflammatory organoid models incorporating multiple cell lineages is vital for novel therapies.
A man who received stem cell therapy in a clinical study in Japan for spinal cord injuries has told NHK how he decided to receive the procedure.
TOKYO (Reuters) - Japanese scientists will test the use of human-induced pluripotent stem cells (iPS) to treat spinal cord injuries, a health ministry panel that approved the research project said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback